CapMan reported Q1 earnings clearly above our and consensus estimates.
Exel’s Q1 report showed the company is making progress in the US as the unit was back to black.
Consti's net sales in Q1 amounted to EUR 59.8m, slightly below our and consensus estimates (EUR 63.
Redeye is optimistic about PulmoStem in lung transplantation following positive results in a preclin...
The market environment continued challenging and Verkkokauppa.
Main points in SRV’s Q1 report related to the write-downs of holdings relating to Russia and Fennovo...
Redeye sees a very solid Q1 from Addnode, with record-high margins in all three Divisions.
Redeye has a positive view of Orexo after the Q1 report, but we see a challenge to stabilising the Z...
Redeye returns with an in-depth take on the Q1 report following the conference call and discussion w...
Redeye bibehåller BioArctics värdering på 250 kronor per aktie efter rapporten.
Adj. EBITA 12% above our expectations Q2’22 should be boosted by heating projects… …and strong L12m ...
Redeye sees a solid Q1 report from Sdiptech on the group level.
Redeye sees a strong Q1’22 report from Stille, where sales in the operating tables segment surprised...
Redeye comments on Medivir’s first quarter report.
Redeye retains its positive view on Proact following a mixed Q1 report with a solid outlook.
Redeye changes our short-term estimates on the back of a challenging environment for Tagmaster.
Redeye does limited changes to estimates following Evolution’s Q1-results which came in close to our...
Sales 0% vs ABGSCe Adj. EBITA 12% vs ABGSCe Europe and RoW driving growth, Nordics more muted Q1’2...
Redeye concludes that Q1 was weaker than Redeye estimates.
Sales up 29% y-o-y, but pressured profitability Write down of account receivable of SEK 15m due to U...
